Ivette Valencia-Sama

NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma

M. Ohh, M. Irwin, Claire M. Robinson, 2020, Cancer Research.

Vitamin D Receptor activation attenuates Hippo pathway effectors and cell survival in metastatic neuroblastoma.

D. Kaplan, M. Irwin, Alexander Gont, 2022, Molecular cancer research : MCR.

Combination mTOR and SHP2 inhibitor treatment of lymphatic malformation endothelial cells.

B. Papsin, E. Propst, M. Irwin, 2022, Microvascular research.

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

M. Ikura, M. Tsao, J. Yeh, 2021, Nature Communications.

Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation

M. Ikura, M. Tsao, J. Yeh, 2019, Nature Communications.

Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor*

Xiaolong Yang, Y. Hao, Dulcie Lai, 2015, The Journal of Biological Chemistry.

Hippo component TAZ functions as a co-repressor and negatively regulates ΔNp63 transcription through TEAD

Xiaolong Yang, Y. Hao, Dulcie Lai, 2015 .